A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. (November 2013)

• Record Type: Journal Article
• Authors: Polyzos, Stergios A.; Kountouras, Jannis; Slavakis, Aristeidis; Zafeiriadou, Efthimia; Patsiaoura, Kalliopi; Katsiki, Evangelia; Zavos, Christos; Papatheodorou, Athanasios; Terpos, Evangelos
• Is Part Of: Biomarkers. Volume 18:Number 7(2013)
• Page Start: 607
• Page End: 613
• Publication Date: 2013-11
• Subjects: Biochemical markers -- Periodicals; 610.28
• DOI: 10.3109/1354750X.2013.838305
• Languages: English
• ISSNs: 1354-750X

Abstract

<abstract> <title>Abstract</title> <p> <italic>Objective</italic>: The potential development of a noninvasive marker predicting nonalcoholic steatohepatitis (NASH).</p> <p> <italic>Methods</italic>: Thirty patients with biopsy-proven nonalcoholic fatty liver disease were evaluated by numerous anthropometric, clinical and biochemical parameters.</p> <p> <italic>Results</italic>: Serum glutamic oxaloacetic transaminase (SGOT; <italic>p</italic> = 0.027), log (erythrocyte sedimentation rate) (ESR; <italic>p</italic> = 0.034) and homocysteine (<italic>p</italic> = 0.041) were associated with NASH independently from gender, age and body mass index. When combined, the regression model provided <italic>R</italic>² = 0.563 (<italic>p</italic> = 0.001) and area under the ROC curve = 0.873 ± 0.066 (<italic>p</italic> &lt; 0.001).</p> <p> <italic>Conclusion</italic>: This noninvasive marker, named HSENSI (acronym of homocysteine, SGOT, ESR, Nonalcoholic Steatohepatitis Index), consists of three low cost, easily measurable parameters and may accurately predict NASH.</p> </abstract>